This study was designed to establish the prevalence of HLA-B*5701 at HIV-1 infected individuals in Brazil. A total of 517 consecutive individuals were followed in this study from February 2009 through July 2011. The p...This study was designed to establish the prevalence of HLA-B*5701 at HIV-1 infected individuals in Brazil. A total of 517 consecutive individuals were followed in this study from February 2009 through July 2011. The presence of HLA-B*5701 was determined by Nested-PCR with HLA-B*57 and HLA-B*5701 sequence-specific primers (PCR-SSP). The expression of HLA-B*57 was negative in the 385 (74.5%) and positive in the 103 (19.9%) of infected individuals. Among these, the expression of HLA-B5701 was positive in the 29 (5.6%) of individuals. No demographic or ethnic differences were found between HLA-B*57/HLA-B*5701 HIV-1 negative patients, with a prevalence of Caucasians (57.1%) individuals. During the period of study, 68 patients were submited to an abacavir contain- ing regimen. The HLA-B*5701 allele was observed in 7 (10.3%) patients, with a significant incidence of Hypersensitivity reactions at 4 of them (p < 0.001). Conclusions: Although Brazilian population consists of a mixture of individuals of Caucasian, African and Native American genetic background, prevalence of HLA-B*5701 in this population is similar to the one found in pure Caucasians.展开更多
文摘基于VHSE(Principal component score vector of hydrophobic,steric,and electronic properties)结构表征方法,采用支持向量机结合遗传算法变量筛选技术,分别建立B*5701和B*5801多肽亲和活性的分类预测模型,其最优线性模型内部验证的灵敏度(Sensitivity,Sen)、特异性(Specificity,Spe)、接受者操作特征曲线下面积(Area under receiver operating characteristics curve,AUC)和马休斯相关系数(Matthews coefficient of correlation,MCC)分别为77.29%、93.99%、93.02%、67.65%(B*5701)和78.08%、89.62%、88.34%、64.73%(B*5801);外部验证的Sen、Spe、AUC和MCC分别为80.02%、94.53%、94.62%、72.09%(B*5701)和77.43%、90.79%、87.98%、66.20%(B*5801)。依据最优模型,分别对B*5701和B*5801配体的亲和特性进行了细致的比较和分析,研究结果可为Abacavir的HLA-B*5701限制性药物毒副作用(Serious Adverse Drug Reactions,SADR)机理研究提供重要的参考依据。
文摘This study was designed to establish the prevalence of HLA-B*5701 at HIV-1 infected individuals in Brazil. A total of 517 consecutive individuals were followed in this study from February 2009 through July 2011. The presence of HLA-B*5701 was determined by Nested-PCR with HLA-B*57 and HLA-B*5701 sequence-specific primers (PCR-SSP). The expression of HLA-B*57 was negative in the 385 (74.5%) and positive in the 103 (19.9%) of infected individuals. Among these, the expression of HLA-B5701 was positive in the 29 (5.6%) of individuals. No demographic or ethnic differences were found between HLA-B*57/HLA-B*5701 HIV-1 negative patients, with a prevalence of Caucasians (57.1%) individuals. During the period of study, 68 patients were submited to an abacavir contain- ing regimen. The HLA-B*5701 allele was observed in 7 (10.3%) patients, with a significant incidence of Hypersensitivity reactions at 4 of them (p < 0.001). Conclusions: Although Brazilian population consists of a mixture of individuals of Caucasian, African and Native American genetic background, prevalence of HLA-B*5701 in this population is similar to the one found in pure Caucasians.
